Literature DB >> 21903105

Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.

Rui D S Prediger1, Filipe C Matheus, Marcelo L Schwarzbold, Marcelo M S Lima, Maria A B F Vital.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting about 1% of the population older than 60 years. Classically, PD is considered as a movement disorder, and its diagnosis is based on the presence of a set of cardinal motor signs that are the consequence of a pronounced death of dopaminergic neurons in the substantia nigra pars compacta. There is now considerable evidence showing that the neurodegenerative processes leading to sporadic PD begin many years before the appearance of the characteristic motor symptoms, and that additional neuronal fields and neurotransmitter systems are also involved in PD, including olfactory structures, amygdala, caudal raphe nuclei, locus coeruleus, and hippocampus. Accordingly, adrenergic and serotonergic neurons are also lost, which seems to contribute to the anxiety in PD. Non-motor features of PD usually do not respond to dopaminergic medication and probably form the major current challenge in the clinical management of PD. Additionally, most studies performed with animal models of PD have investigated their ability to induce motor alterations associated with advanced phases of PD, and some studies begin to assess non-motor behavioral features of the disease. The present review attempts to examine results obtained from clinical and experimental studies to provide a comprehensive picture of the neurobiology and current and potential treatments for anxiety in PD. The data reviewed here indicate that, despite their high prevalence and impact on the quality of life, anxiety disorders are often under-diagnosed and under-treated in PD patients. Moreover, there are currently few clinical and pre-clinical studies underway to investigate new pharmacological agents for relieving these symptoms, and we hope that this article may inspire clinicians and researchers devote to the studies on anxiety in PD to change this scenario. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903105     DOI: 10.1016/j.neuropharm.2011.08.039

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  43 in total

Review 1.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

2.  The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Authors:  Marissa Giovanna Schamne; Josiel Mileno Mack; Morgana Moretti; Filipe Carvalho Matheus; Roger Walz; Laurence Lanfumey; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2018-05-28       Impact factor: 3.911

3.  Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice.

Authors:  Sara Ferrazzo; Ozge Gunduz-Cinar; Nadia Stefanova; Gabrielle A Pollack; Andrew Holmes; Claudia Schmuckermair; Francesco Ferraguti
Journal:  Neurobiol Dis       Date:  2019-01-21       Impact factor: 5.996

4.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

Review 5.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 6.  Anxiety in Parkinson's disease: identification and management.

Authors:  Jack J Chen; Laura Marsh
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

7.  Multimodal MRI evaluation of parkinsonian limbic pathologies.

Authors:  Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2019-01-16       Impact factor: 4.673

Review 8.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

9.  Neural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disorders.

Authors:  A Lotan; T Lifschytz; A Slonimsky; E C Broner; L Greenbaum; S Abedat; Y Fellig; H Cohen; O Lory; G Goelman; B Lerer
Journal:  Mol Psychiatry       Date:  2013-09-17       Impact factor: 15.992

10.  Variables associated with physical health-related quality of life in Parkinson's disease patients presenting for deep brain stimulation.

Authors:  Alexandre Paim Diaz; Fernando Cini Freitas; Maria Emília de Oliveira Thais; Fernando Zanela da Silva Areas; Marcelo Liborio Schwarzbold; Rodrigo Debona; Jean Costa Nunes; Ricardo Guarnieri; Daniel Martinez-Ramirez; Rui Daniel Prediger; Aparna Wagle Shukla; Marcelo Neves Linhares; Roger Walz
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.